Ninepoint Partners’s AbbVie ABBV Stock Holding History

Ninepoint Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$299K	Buy	+1,187	New	+$255K	0.02%	142
2026 Q1	–	Sell	-797	Closed	-$182K	–	150
2025 Q4	$182K	Sell	797 -1,485	-65%	-$338K	0.02%	140
2025 Q3	$528K	Buy	+2,282	New	+$465K	0.07%	89
2025 Q2	–	Sell	-4,983	Closed	-$1.04M	–	88
2025 Q1	$1.04M	Buy	+4,983	New	+$969K	0.17%	60
2022 Q4	–	Sell	-2,933	Closed	-$394K	–	83
2022 Q3	$394K	Buy	+2,933	New	+$421K	0.05%	55

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Ninepoint Partners's ABBV Position: Q2 2026 in Review

Ninepoint Partners opened a new position in AbbVie (ABBV) in Q2 2026: 1,187 shares worth $299K. The stake represents 0.02% of the portfolio and ranks #142 among its holdings. This is a return to the name: Ninepoint Partners previously reported a position in ABBV as recently as Q4 2025.

Ninepoint Partners first reported a position in ABBV in Q3 2022 and has held it in 5 quarters since. The position peaked at $1.04M in Q1 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Ninepoint Partners held 1,187 shares of AbbVie worth $299K as of Q2 2026.
AbbVie was a new Ninepoint Partners position in Q2 2026.
AbbVie made up 0.02% of Ninepoint Partners's portfolio in Q2 2026, its #142 holding.
Ninepoint Partners first reported a position in AbbVie in Q3 2022 and has held it in 5 quarters since.
Ninepoint Partners's AbbVie position peaked at $1.04M in Q1 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Ninepoint Partners's 13F filing for Q2 2026, filed 11 Aug 2026.